B+
Bull case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
EDSA
Edesa BiotechBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
EDSA still has upside optionality because paridiprubart showed statistically significant mortality benefit in the February 24, 2026 8-K, and the company also has external program support through government-backed funding and study activity [#8-K-2026-02-24] [#10-Q-2026-02-13].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.7.
What can break
Dilutive financing or additional ATM usage
Momentum
15
Value
41
Sentiment
85
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $8.50 · Bear $2.00Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $16.33
Why
Momentum15 · Δ7d +1.6
Value41 · Δ7d -0.0
Sentiment85 · Δ7d +3.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +3.7.
Contradictions & invalidation
- • Dilutive financing or additional ATM usage
- • Low liquidity and sparse coverage can amplify downside on limited news
- • The same 10-Q also makes clear that Edesa remains a cash-consuming micro-cap biotech with going-concern uncertainty and dependence on additional financing, so even good clinical signals can be offset by dilution, timing slippage, or failure to convert data into a regulatory path [#10-Q-2026-02-13].
Catalyst clock
2026-06-30
EB06 vitiligo study start is a tangible 2026 checkpoint
Lead driver: Sentiment · See AI snapshot
Momentum
15
9% active weight
Current posture
7d trendImproving
Δ7d
+1.6
Δ21d
+13.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
85
62% active weight
Current posture
7d trendImproving
Δ7d
+3.7
Δ21d
+1.8
Why this grade
Composite grade B. Momentum 15.2 / Value 41.2 / Sentiment 85.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$54.47M
Beta
0.21
Shares Out
9.64M
P/E (TTM) · Derived
-4.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.19
Rev YoY
-100.0%
EPS YoY
+141.0%
Gross Margin
-24138.0%
Op Margin
-
Net Debt
-$10.79M
Current Ratio
2.76
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data